mRNA pancreatic cancer vaccine trial shows promising results in phase I study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Results from a phase I trial at Memorial Sloan Kettering Cancer Center suggest that treatment with mRNA vaccines (autogene cevumeran) cause an effective and lasting immune response in some patients with pancreatic cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Noetik and Memorial Sloan Kettering Cancer Center have partnered to advance the next generation of cancer biology world models. The collaboration brings together MSK’s depth of oncology expertise and research resources with Noetik’s AI and data foundry capabilities to enable a more diverse and comprehensive model view of cancer development and enhance clinical outcomes.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login